flecainide has been researched along with Coronary Disease in 30 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flecainide, a new antiarrhythmic drug (group 1 according to the classification after Vaughan Williams), is used in the treatment of atrial and ventricular arrhythmias." | 9.06 | [Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients]. ( Boldt, J; Görlach, G; Hempelmann, G; Kling, D; Russ, W, 1987) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 9.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| "Efficacy of flecainide was investigated in 50 patients with sustained ventricular tachycardia (n = 38) or ventricular fibrillation (n = 12) during a 4-week in-hospital and 1-year follow-up period." | 7.68 | Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. ( Crijns, HJ; Kingma, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM; Wesseling, H, 1990) |
| "Thirty-two patients received flecainide acetate for nonsustained ventricular tachycardia after having had unsuccessful treatment with a mean of four antiarrhythmic drugs." | 7.67 | Flecainide in the treatment of nonsustained ventricular tachycardia. ( Chapman, PD; Dougherty, AH; Kim, SS; Lal, R; Naccarelli, GV; Rinkenberger, RL; Ruffy, R; Schechtman, KB; Troup, PJ, 1986) |
| "The effect of flecainide acetate, a class 1c antiarrhythmic agent, was examined in 15 patients with recurrent ventricular tachycardia." | 7.67 | Effect of intravenous and oral flecainide on ventricular tachycardia. ( Cheesman, M; Dancy, M; Ward, DE, 1986) |
| "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 +/- 87 mg [mean +/- standard deviation])." | 7.67 | Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. ( Estes, M; Garan, H; Griffith, LS; Heine, DL; Platia, EV; Reid, PR; Ruskin, JN, 1985) |
| "After an initial pilot study in five patients, the effect of flecainide on chronic ventricular arrhythmias was tested during 48-hour oral administration of 250 mg twice a day in nine further patients with previously drug-resistant chronic, stable ventricular arrhythmias." | 7.66 | [Effect of flecainide on chronic ventricular arrhythmias (author's transl)]. ( Abendroth, RR; Bluschke, V; Breithardt, G; Seipel, L, 1982) |
| "The hemodynamic effects of flecainide acetate, a new class I antiarrhythmic agent, were studied in 10 patients with coronary heart disease." | 7.66 | Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease. ( Collignon, P; Kulbertus, HE; Legrand, V; Vandormael, M, 1983) |
| "Flecainide, a new antiarrhythmic drug (group 1 according to the classification after Vaughan Williams), is used in the treatment of atrial and ventricular arrhythmias." | 5.06 | [Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients]. ( Boldt, J; Görlach, G; Hempelmann, G; Kling, D; Russ, W, 1987) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 5.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| "Efficacy of flecainide was investigated in 50 patients with sustained ventricular tachycardia (n = 38) or ventricular fibrillation (n = 12) during a 4-week in-hospital and 1-year follow-up period." | 3.68 | Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. ( Crijns, HJ; Kingma, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM; Wesseling, H, 1990) |
| "Flecainide has unusual electrophysiologic properties and a high potency for the suppression of ventricular tachyarrhythmias." | 3.67 | Effects of flecainide on ventricular function: clinical and experimental correlations. ( Ikeda, N; Josephson, MA; Singh, BN, 1984) |
| "To assess flecainide's ability to suppress ventricular fibrillation during reperfusion, we compared flecainide acetate (2 mg/kg i." | 3.67 | Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. ( Bolster, DE; Lederman, SN; Strauss, HC; Wenger, TL, 1989) |
| "Thirty-two patients received flecainide acetate for nonsustained ventricular tachycardia after having had unsuccessful treatment with a mean of four antiarrhythmic drugs." | 3.67 | Flecainide in the treatment of nonsustained ventricular tachycardia. ( Chapman, PD; Dougherty, AH; Kim, SS; Lal, R; Naccarelli, GV; Rinkenberger, RL; Ruffy, R; Schechtman, KB; Troup, PJ, 1986) |
| "The effect of flecainide acetate, a class 1c antiarrhythmic agent, was examined in 15 patients with recurrent ventricular tachycardia." | 3.67 | Effect of intravenous and oral flecainide on ventricular tachycardia. ( Cheesman, M; Dancy, M; Ward, DE, 1986) |
| "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 +/- 87 mg [mean +/- standard deviation])." | 3.67 | Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. ( Estes, M; Garan, H; Griffith, LS; Heine, DL; Platia, EV; Reid, PR; Ruskin, JN, 1985) |
| "The haemodynamic effects of flecainide were compared in three different subsets of patients with documented coronary disease." | 3.67 | Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy. ( Collignon, P; Kulbertus, HE; Legrand, V; Materne, P; Vandormael, M, 1985) |
| "After an initial pilot study in five patients, the effect of flecainide on chronic ventricular arrhythmias was tested during 48-hour oral administration of 250 mg twice a day in nine further patients with previously drug-resistant chronic, stable ventricular arrhythmias." | 3.66 | [Effect of flecainide on chronic ventricular arrhythmias (author's transl)]. ( Abendroth, RR; Bluschke, V; Breithardt, G; Seipel, L, 1982) |
| "The hemodynamic effects of flecainide acetate, a new class I antiarrhythmic agent, were studied in 10 patients with coronary heart disease." | 3.66 | Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease. ( Collignon, P; Kulbertus, HE; Legrand, V; Vandormael, M, 1983) |
| "Flecainide was prescribed with a median posology of 150 mg per day, mostly as LP form (64%)." | 1.33 | [Flecainide acetate utilisation review among general practitioners and hospital or office-based cardiologists in France. Obepine: observational study of flecainide]. ( Danchin, N; Jaillon, P; Le Heuzey, JY; Liard, F; Lièvre, M, 2006) |
| "flecainide were examined in rats with postischemic left ventricular dysfunction." | 1.28 | [Negative inotropic effect of flecainide on the post-ischemic heart with limited contractile function]. ( Beyer, M; Hoffmeister, HM; Hörmann, HP; Seipel, L, 1990) |
| "Flecainide acetate has been shown to be a potent antiarrhythmic agent which is active for more than 8 h, whether given intravenously or orally." | 1.27 | The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease. ( Hugenholtz, PG; Lubsen, J; Serruys, PW; Van Den Brand, M; Vanhaleweyk, G; Verdouw, P, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (66.67) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 2 (6.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liard, F | 1 |
| Le Heuzey, JY | 1 |
| Jaillon, P | 1 |
| Lièvre, M | 1 |
| Danchin, N | 1 |
| Rivard, L | 1 |
| Sinno, H | 1 |
| Shiroshita-Takeshita, A | 1 |
| Schram, G | 1 |
| Leung, TK | 1 |
| Nattel, S | 1 |
| Bluschke, V | 1 |
| Breithardt, G | 2 |
| Abendroth, RR | 1 |
| Seipel, L | 3 |
| Klempt, HW | 1 |
| Nayebagha, A | 1 |
| Fabry, E | 1 |
| Hellestrand, KJ | 2 |
| Josephson, MA | 2 |
| Ikeda, N | 1 |
| Singh, BN | 2 |
| Milne, JR | 1 |
| Bexton, RS | 1 |
| Burnett, PJ | 1 |
| Debbas, NM | 1 |
| Camm, AJ | 1 |
| Legrand, V | 2 |
| Vandormael, M | 2 |
| Collignon, P | 2 |
| Kulbertus, HE | 2 |
| Anderson, JL | 2 |
| Lutz, JR | 1 |
| Allison, SB | 1 |
| Serruys, PW | 1 |
| Vanhaleweyk, G | 1 |
| Van Den Brand, M | 1 |
| Verdouw, P | 1 |
| Lubsen, J | 1 |
| Hugenholtz, PG | 1 |
| Lui, HK | 1 |
| Lee, G | 1 |
| Dietrich, P | 1 |
| Low, RI | 1 |
| Mason, DT | 1 |
| Borggrefe, M | 1 |
| Yeh, HL | 1 |
| Pratt, CM | 1 |
| Waldo, AL | 1 |
| Karagounis, LA | 1 |
| Fauchier, L | 1 |
| Babuty, D | 1 |
| Autret, ML | 1 |
| Poret, P | 1 |
| Cosnay, P | 1 |
| Fauchier, JP | 1 |
| Winslow, E | 1 |
| Mason, R | 1 |
| Antzelevitch, C | 1 |
| Sicouri, S | 1 |
| Litovsky, SH | 1 |
| Lukas, A | 1 |
| Krishnan, SC | 1 |
| Di Diego, JM | 1 |
| Gintant, GA | 1 |
| Liu, DW | 1 |
| van Wijk, LM | 1 |
| Crijns, HJ | 1 |
| Kingma, HJ | 1 |
| van Gilst, WH | 1 |
| van Gelder, IC | 1 |
| Wesseling, H | 1 |
| Lie, KI | 1 |
| Faucon, G | 2 |
| Aupetit, JF | 2 |
| Gerentes-Chassagne, I | 2 |
| Loufoua-Moundanga, J | 2 |
| Larbre, JP | 1 |
| Timour, Q | 2 |
| Kioueh, I | 1 |
| Hoffmeister, HM | 1 |
| Hörmann, HP | 1 |
| Beyer, M | 1 |
| Matsuo, S | 1 |
| Koh, Y | 1 |
| Sato, R | 1 |
| Munakata, K | 1 |
| Kishida, H | 1 |
| Lederman, SN | 1 |
| Wenger, TL | 1 |
| Bolster, DE | 1 |
| Strauss, HC | 1 |
| Li, XY | 1 |
| Kling, D | 1 |
| Boldt, J | 1 |
| Russ, W | 1 |
| Görlach, G | 1 |
| Hempelmann, G | 1 |
| Goedel-Meinen, L | 1 |
| Hofmann, M | 1 |
| Schmidt, G | 1 |
| Barthel, P | 1 |
| Baedeker, W | 1 |
| Blömer, H | 1 |
| Lal, R | 1 |
| Chapman, PD | 1 |
| Naccarelli, GV | 1 |
| Schechtman, KB | 1 |
| Rinkenberger, RL | 1 |
| Troup, PJ | 1 |
| Kim, SS | 1 |
| Dougherty, AH | 1 |
| Ruffy, R | 1 |
| Ward, DE | 1 |
| Cheesman, M | 1 |
| Dancy, M | 1 |
| Kaul, S | 1 |
| Hopkins, J | 1 |
| Kvam, D | 1 |
| Platia, EV | 1 |
| Estes, M | 1 |
| Heine, DL | 1 |
| Griffith, LS | 1 |
| Garan, H | 1 |
| Ruskin, JN | 1 |
| Reid, PR | 1 |
| Materne, P | 1 |
2 reviews available for flecainide and Coronary Disease
| Article | Year |
|---|---|
Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Coronary Disease; Encaini | 1984 |
Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells.
Topics: 4-Aminopyridine; Action Potentials; Age Factors; Amiloride; Animals; Caffeine; Calcium; Calcium Chan | 1991 |
4 trials available for flecainide and Coronary Disease
| Article | Year |
|---|---|
[Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Coronary Disease; Electrocardiogr | 1982 |
[Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients].
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modality Therapy; Coronary Artery Bypass; C | 1987 |
[Effect of class I anti-arrhythmia agents on the signal-averaged ECG].
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Clinical Trials as Topic; Coronary Disease; Disopyr | 1988 |
Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease.
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Double-Blind Method; Flecainide; Heart; Heart Rate; H | 1985 |
24 other studies available for flecainide and Coronary Disease
| Article | Year |
|---|---|
[Flecainide acetate utilisation review among general practitioners and hospital or office-based cardiologists in France. Obepine: observational study of flecainide].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output, Low; Cardiology; Coronary Disease | 2006 |
The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel B | 2007 |
[Effect of flecainide on chronic ventricular arrhythmias (author's transl)].
Topics: Adult; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Arrhythmias, Cardiac; Cardiac Complexes, Prema | 1982 |
Effects of flecainide on ventricular function: clinical and experimental correlations.
Topics: Adult; Aged; Animals; Anti-Arrhythmia Agents; Cardiac Catheterization; Coronary Disease; Female; Fle | 1984 |
Class 1 antiarrhythmic drugs--characteristic electrocardiographic differences when assessed by atrial and ventricular pacing.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Disop | 1984 |
Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease.
Topics: Adult; Anti-Arrhythmia Agents; Cardiac Output; Coronary Disease; Depression, Chemical; Electrocardio | 1983 |
Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Blood Pressure; Bundle of His; Cardiac Pa | 1983 |
The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease.
Topics: Adult; Anti-Arrhythmia Agents; Blood Pressure; Cardiac Pacing, Artificial; Coronary Disease; Female; | 1983 |
Flecainide-induced QT prolongation and ventricular tachycardia.
Topics: Coronary Disease; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Piperidines; Tachycard | 1982 |
[Electrophysiological effects of flecainide on stimulus-inducible ventricular tachycardia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiograp | 1982 |
Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting "Deadly Medicine" to the test.
Topics: Anti-Arrhythmia Agents; Coronary Disease; Drug Approval; Drug Utilization; Encainide; Evaluation Stu | 1997 |
Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; Flec | 1998 |
Comparative hemodynamic effects of Org 7797, flecainide, and propafenone in anesthetized pigs with developing myocardial infarcts.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Dose-Response Relationship, Drug; Estrenes; Femal | 1992 |
Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Coronary Disease; Electric Stimulation; Electrocardiography, Ambulatory; Exercise Test; Female | 1990 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
Class Ic antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Disease; Coronary Vesse | 1991 |
[Negative inotropic effect of flecainide on the post-ischemic heart with limited contractile function].
Topics: Animals; Blood Pressure; Coronary Disease; Flecainide; Heart Rate; Male; Myocardial Contraction; Myo | 1990 |
Electrophysiological effects of flecainide on guinea pig ventricular muscle in high [K+]o, acidosis and hypoxia.
Topics: Acidosis; Action Potentials; Animals; Arrhythmias, Cardiac; Coronary Disease; Female; Flecainide; Gu | 1987 |
Effects of flecainide on occlusion and reperfusion arrhythmias in dogs.
Topics: Animals; Blood Pressure; Coronary Disease; Dogs; Electrocardiography; Flecainide; Heart Rate; Myocar | 1989 |
[A preliminary study on oral flecainide acetate in treating tachyarrhythmias].
Topics: Aged; Aged, 80 and over; Cardiac Complexes, Premature; Coronary Disease; Electrocardiography; Feedin | 1989 |
Flecainide in the treatment of nonsustained ventricular tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; Flecainide; Foll | 1986 |
Effect of intravenous and oral flecainide on ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Dise | 1986 |
Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; | 1985 |
Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy.
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Electrocardiography; Female; Flecainide; Heart Rate; | 1985 |